( June 25, 2026, 12:06 PM EDT) -- WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel affirmed a Massachusetts federal judge’s finding that a biopharmaceutical company’s patent claims were invalid as anticipated by a public disclosure of a chemical compound central to the patent, leaving in place a win for Pfizer Inc. as it defended its treatment for COVID-19....